Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus

Annual Review of Immunology

Volumn 25, Issue , 2007, Pages 587-617

  Hislop, Andrew D ^a   Taylor, Graham S ^a   Sauce, Delphine ^a   Rickinson, Alan B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cellular immunity; Immunodominance; Immunological memory

Indexed keywords

ANTIGEN; CYTOKINE RECEPTOR; T LYMPHOCYTE RECEPTOR;

BIOLOGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KINETICS; CELL MIGRATION; CELL SIZE; CELLULAR IMMUNITY; COMPREHENSION; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; EVOLUTION; HEMOPHAGOCYTIC SYNDROME; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HOMEOSTASIS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOPATHOLOGY; INFECTIOUS MONONUCLEOSIS; INNATE IMMUNITY; LYMPHOPROLIFERATIVE DISEASE; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK; TUMOR; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; X CHROMOSOME LINKED DISORDER;

ANIMALS; CELL TRANSFORMATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INFECTIOUS MONONUCLEOSIS; INTERLEUKIN-15; KILLER CELLS, NATURAL; T-LYMPHOCYTES;

EID: 34247872819     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.25.022106.141553     Document Type: Review

References (155)

1. Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, et al. 2006. A cohort study among university students: identification of risk factors for EBV seroconversion and infectious mononucleosis. Clin. Infect. Dis. 43:276-82
2. Chan CW, Chiang AK, Chan KH, Lau AS. 2003. Epstein-Barr virus-associated infectious mononucleosis in Chinese children. Pediatr. Infect. Dis. J. 22:974-78
3. Rickinson AB, Kieff E. 2006. Epstein-Barr virus. In Fields Virology, ed. BN Fields, DM Knipe, PM Howley, RM Chanock, JL Melnick, et al. Philadelphia: Lippincott, Williams & Wilkins. In press
4. Thorley-Lawson DA. 2001. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1:75-82
5. Kuppers R. 2003. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol. 3:801-12
6. Shannon-Lowe CD, Neuhierl B, Baldwin G, Rickinson AB, Delecluse HJ. 2006. From the cover: resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc. Natl. Acad. Sci. USA 103:7065-70
7. Fafi-Kremer S, Morand P, Brion JP, Pavese P, Baccard M, et al. 2005. Long-term shedding of infectious Epstein-Barr virus after infectious mononucleosis. J. Infect. Dis. 191:985-89
8. Balfour HH Jr, Holman CJ, Hokanson KM, Lelonek MM, Giesbrecht JE, et al. 2005. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J. Infect. Dis. 192:1505-12
9. Braud VM, Tomasec P, Wilkinson GW. 2002. Viral evasion of natural killer cells during human cytomegalovirus infection. Curr. Top. Microbiol. Immunol. 269:117-29
10. Vidal S, Lanier LL. 2006. NK cell recognition of mouse cytomegalovirus-infected cells. Curr. Top. Microbiol. Immunol. 298:183-206
11. Usherwood EJ, Meadows SK, Crist SG, Bellfy SC, Sentman CL. 2005. Control of murine γ herpesvirus infection is independent of NK cells. Eur. J. Immunol. 35:2956-61
12. Williams H, McAulay K, Macsween KF, Gallacher NJ, Higgins CD, et al. 2005. The immune response to primary EBV infection: a role for natural killer cells. Br. J. Haematol. 129:266-74
13. Lotz M, Tsoukas CD, Fong S, Carson DA, Vaughan JH. 1985. Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-γ. Eur. J. Immunol. 15:520-25
14. Deleted in proof
15. O'Reilly RJ, Small TN, Papadopoulos EB, Lucas KG, Lacerda JF, Koulova L. 1997. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol. Rev. 157:195-216
16. Pappworth IY, Wang EC, Rowe M. 2007. The switch from latent to productive infection in Epstein-Barr virus infected B cells is associated with sensitization to NK cell killing. J. Virol. 81:474-82
17. McNally JM, Welsh RM. 2002. Bystander T cell activation and attrition. Curr. Top. Microbiol. Immunol. 263:29-41
18. Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. 2001. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 15:579-89
19. Annels NE, Callan MFC, Tan L, Rickinson AB. 2000. Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response. J. Immunol. 165:4831-41
20. + virus-specific cytotoxic T cells which recognize Epstein-Barr virus lytic antigen BHRF1. Virology 219:489-92
21. Steven NM, Leese AM, Annels N, Lee S, Rickinson AB. 1996. Epitope focusing in the primary cytotoxic T-cell response to Epstein-Barr virus and its relationship to T-cell memory. J Exp. Med. 184:1801-13
22. Steven NM, Annels N, Kumar A, Leese A, Kurilla MG, Rickinson AB. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185:1605-17
23. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187:1395-402
24. +-activated T cells in primary EBV infection. J. Immunol. 163:5735-40
25. + T cell responses in EBV infection. J. Immunol. 167:4450-57
26. + T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195:893-905
27. + immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J. Exp. Med. 201:349-60
28. Woodberry T, Suscovich TJ, Henry LM, Davis JK, Frahm N, et al. 2005. Differential targeting and shifts in the immunodominance of Epstein-Barr virus-specific CD8 and CD4 T cell responses during acute and persistent infection. J. Infect. Dis. 192:1513-24
29. + T cells and the virus-host balance. J. Clin. Invest. 115:2546-55
30. + T cell selection, function, and death in the primary immune response in vivo. J. Clin. Invest. 106:1251-61
31. + T cells. J. Immunol. 168:4184-91
32. + T cells during primary infection. J. Immunol. 170:2590-98
33. + T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood 100:933-40
34. + T-lymphocytes in acute infectious mononucleosis supporting their susceptibility to programmed cell death. Blood 82:521-27
35. + pool with distinct phenotypic and migratory characteristics. J. Immunol. 167:212-20
36. + T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J. Immunol. 167:2019-29
37. + T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers. Virology 264:289-97
38. Saulquin X, Ibisch C, Peyrat MA, Scotet E, Hourmant M, et al. 2000. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur. J. Immunol. 30:2531-39
39. Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, et al. 2006. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J. Immunol. 176:4094-101
40. Crough T, Burrows JM, Fazou C, Walker S, Davenport MP, Khanna R. 2005. Contemporaneous fluctuations in T cell responses to persistent herpes virus infections. Eur. J. Immunol. 35:139-49
41. + T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech. Ageing Dev. 124:477-85
42. Khan N, Hislop A, Gudgeon N, Cobbold M, Khanna R, et al. 2004. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J. Immunol. 173:7481-89
43. Maini MK, Gudgeon N, Wedderburn LR, Rickinson AB, Beverley PCL. 2000. Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J. Immunol. 165:5729-37
44. + T cell response to Epstein-Barr virus during primary and persistent infection. J. Exp. Med. 198:903-11
45. + T cells in protection against CMV disease. Blood 101:2686-92
46. + T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J. Clin. Invest. 107:121-30
47. + T helper cells. Eur. J. Immunol. 34:2500-9
48. + T-lymphocyte response to Epstein-Barr virus nuclear antigen 1. J. Virol. 74:6748-59
49. + cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood 99:3302-9
50. + helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res. 65:1577-86
51. + T-helper 1 responses. J. Virol. 75:8649-59
52. + T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J. Virol. 79:4896-907
53. Dukers DF, Meij P, Vervoort MBHJ, Vos W, Scheper RJ, et al. 2000. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J. Immunol. 165:663-70
54. Marshall NA, Vickers MA, Barker RN. 2003. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J. Immunol. 170:6183-89
55. Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. 2006. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J. Exp. Med. 203:995-1006
56. Landais E, Saulquin X, Scotet E, Trautmann L, Peyrat MA, et al. 2004. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 103:1408-16
57. + T-cell clones. J. Virol. 65:3821-28
58. Deleted in proof
59. Yewdell JW, Bennink JR. 1999. Immunodominance in major histocompatability complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:51-88
60. Scotet E, David-Ameline J, Peyrat MA, Moreau-Aubry A, Pinczon D, et al. 1996. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J. Exp. Med. 184:1791-800
61. Keating S, Prince S, Jones M, Rowe M. 2002. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J. Virol. 76:8179-88
62. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ. 2002. Viral immune evasion: a masterpiece of evolution. Immunogenetics 54:527-42
63. Deleted in proof
64. Rivailler P, Cho Y, Wang F. 2002. Complete genomic sequence of an Epstein-Barr virus-related herpesvirus naturally infecting a New World primate: a defining point in the evolution of oncogenic lymphocryptoviruses. J. Virol. 76:12055-68
65. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. 2005. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol. Rev. 207:145-57
66. Landais E, Saulquin X, Bonneville M, Houssaint E. 2005. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected B cells following capture of BHRF1 antigen. J. Immunol. 175:7939-46
67. Spriggs M, Armitage R, Comeau M, Strockbine L, Farrah T, et al. 1996. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J. Virol. 70:5557-63
68. Molesworth SJ, Lake CM, Borza CM, Turk SM, Hutt-Fletcher LM. 2000. Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J. Virol. 74:6324-32
69. Ressing ME, vanLeeuwen D, Verreck FAW, Gomez R, Heemskerk B, et al. 2003. Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc. Natl. Acad. Sci. USA 100:11583-88
70. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765
71. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, et al. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157-68
72. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, et al. 1992. Localisation of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-78
73. Chapman ALN, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. 2001. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T cell-based therapy. Cancer Res. 61:6219-26
74. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB. 1997. Conserved cytotoxic T lymphocyte (CTL) epitopes within Epstein- Barr virus (EBV) latent membrane protein 2, a potential target for CTL-based tumor therapy. J. Immunol. 158:3325-34
75. Lee SP, Thomas WA, Blake NW, Rickinson AB. 1996. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. Eur. J. Immunol. 26:1875-83
76. + T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int. J. Cancer 99:93-99
77. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, et al. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen 1. Nature 375:685-88
78. Dantuma NP, Shapiro A, Masucci MG. 2002. Avoiding proteasomal processing: the case for EBNA1. Curr. Top. Microbiol. Immunol. 269:23-36
79. + T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 165:7078-87
80. Lee SP, Brooks JM, Al-Jarrah H, Thomas WA, Haigh TA, et al. 2004. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J. Exp. Med. 199:1409-20
81. + T lymphocytes. J. Exp. Med. 199:459-70
82. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J. Exp. Med. 199:1421-31
83. Yin Y, Manoury B, Fahraeus R. 2003. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301:1371-74
84. Yewdell JW, Reits E, Neefjes J. 2003. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3:952-61
85. Gottschalk S, Rooney CM, Heslop HE. 2005. Post-transplant lymphoproliferative disorders. Annu. Rev. Med. 56:29-44
86. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191:1649-60
87. + T cells. Cancer Res. 62:7195-99
88. + T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes. J. Virol. 80:8263-66
89. + EBV-specific CTLs. J. Immunol. 158:3619-25
90. + T cells specific for an MHC class II promiscuous epitope. J. Immunol. 169:2172-79
91. + Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 169:1593-603
92. + T cells in the control of mouse Burkitt lymphoma in vivo. J. Clin. Invest. 114:542-50
93. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, et al. 2005. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307:593-96
94. + T cells. J. Immunol. 177:3746-56
95. + T-cell responses. Curr. Opin. Immunol. 16:259-63
96. Argaet VP, Schmidt CW, Burrows SR, Silins SL, Kurilla MG, et al. 1994. Dominant selection of an invariant T-cell antigen receptor in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 180:2335-40
97. + T cells can dominate in the peripheral circulation for at least 18 years. Blood 106:4412-13
98. + T cell memory in vivo. Eur. J. Immunol. 28:4382-90
99. Burrows SR, Silins SL, Moss DJ, Khanna R, Misko IS, Argaet VP. 1995. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J. Exp. Med. 182:1703-15
100. Kjer-Nielsen L, Clements CS, Purcell AW, Brooks AG, Whisstock JC, et al. 2003. A structural basis for the selection of dominant αβ T cell receptors in antiviral immunity. Immunity 18:53-64
101. Miles JJ, Elhassen D, Borg NA, Silins SL, Tynan FE, et al. 2005. CTL recognition of a bulged viral peptide involves biased TCR selection. J. Immunol. 175:3826-34
102. Tynan FE, Borg NA, Miles JJ, Beddoe T, El-Hassen D, et al. 2005. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I: implications for T-cell receptor engagement and T-cell immunodominance. J. Biol. Chem. 280:23900-9
103. Couedel E, Bodinier M, Peyrat MA, Bonneville M, Davodeau F, Lang F. 1999. Selection and long-term persistence of reactive CTL clones during an EBV chronic response are determined by avidity, CD8 variable contribution compensating for differences in TCR affinities. J. Immunol. 162:6351-58
104. + cytotoxic T lymphocytes during primary and persistent infection. Int. Immunol. 9:1745-55
105. Davenport MP, Fazou C, McMichael AJ, Callan MFC. 2002. Clonal selection, clonal senescence, and clonal succession: the evolution of the T cell response to infection with a persistent virus. J. Immunol. 168:3309-17
106. + T cell populations specific for persistent DNA viruses. J. Exp. Med. 202:1349-61
107. Misko IS, Cross SM, Khanna R, Elliott SL, Schmidt C, et al. 1999. Cross-reactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. Proc. Natl. Acad. Sci. USA 96:2279-84
108. + T-cell cross reactivity and heterologous immunity. Immunol. Rev. 211:164-81
109. + T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J. Clin. Invest. 115:3602-12
110. + T cell subsets during acute Epstein-Barr and human immunodeficiency virus infections in humans. J. Infect. Dis. 182:451-58
111. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:379-85
112. Woodberry T, Suscovich TJ, Henry LM, August M, Waring MT, et al. 2005. αEβ7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL population. J. Immunol. 175:4355-62
113. + T cells during persistent infection. Blood 106:558-65
114. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4:1191-98
115. Schluns KS, Lefrancois L. 2003. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol. 3:269-79
116. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. 2004. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. USA 101:16004-9
117. Lang KS, Recher M, Navarini AA, Harris NL, Löhning L, et al. 2005. Inverse correlation between IL-7 receptor expression and CD8 T cell exhaustion during persistent antigen stimulation. Eur. J. Immunol. 35:738-45
118. Sauce D, Larsen M, Curnow SJ, Leese AM, Moss PA, et al. 2006. EBV-associated mononucleosis leads to long-term global deficit in T cell responsiveness to IL-15. Blood 108:11-18
119. + T cells. Blood 106:2091-98
120. + T cell differentiation: contrasting pictures in blood and tonsillar lymphoid tissue. J. Infect. Dis. 195:268-78
121. Dubois S, Mariner J, Waldmann TA, Tagaya Y. 2002. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17:537-47
122. Deleted in proof
123. Greenwald RJ, Freeman GJ, Sharpe AH. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515-48
124. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-87
125. + T cell survival in HIV infection. J. Exp. Med. 203:2281-92
126. Silins SL, Sherritt MA, Silleri JM, Cross SM, Elliott SL, et al. 2001. Symptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 98:3739-44
127. Hurme M, Haanpaa M, Nurmikko T, Wang XY, Virta M, et al. 2003. IL-10 gene polymorphism and herpesvirus infections. J. Med. Virol. 70:S48-50
128. + lymphoproliferative disease in hu PBL-SCID mice. Blood 105:1558-65
129. Sullivan JL, Woda BA. 1989. X-linked lymphoproliferative syndrome. Immunodefic. Rev. 1:325-47
130. Gaspar HB, Sharifi R, Gilmour KC, Thrasher AJ. 2002. X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective. Br. J. Haematol. 119:585-95
131. Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, et al. 1998. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc. Natl. Acad. Sci. USA 95:13765-70
132. Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, et al. 1998. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat. Genet. 20:129-35
133. Sayos J, Wu C, Morra M, Wang N, Zhang X, et al. 1998. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the coreceptor SLAM. Nature 395:462-69
134. + T cells. J. Clin. Invest. 115:1049-59
135. Cannons JL, Yu LJ, Jankovic D, Crotty S, Horai R, et al. 2006. SAP regulates T cell-mediated help for humoral immunity by a mechanism distinct from cytokine regulation. J. Exp. Med. 203:1551-65
136. Crotty S, Kersh EN, Cannons J, Schwartzberg PL, Ahmed R. 2003. SAP is required for generating long-term humoral immunity. Nature 421:282-87
137. Czar MJ, Kersh EN, Mijares LA, Lanier G, Lewis J, et al. 2001. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc. Natl. Acad. Sci. USA 98:7449-54
138. Pasquier B, Yin L, Fondaneche MC, Relouzat F, Bloch-Queyrat C, et al. 2005. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J. Exp. Med. 201:695-701
139. Nichols KE, Hom J, Gong SY, Ganguly A, Ma CS, et al. 2005. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat. Med. 11:340-45
140. Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, et al. 2000. X-linked lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 192:337-46
141. Bottino C, Falco M, Parolini S, Marcenaro E, Augugliaro R, et al. 2001. NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J. Exp. Med. 194:235-46
142. Williams H, Macsween K, McAulay K, Higgins C, Harrison N, et al. 2004. Analysis of immune activation and clinical events in acute infectious mononucleosis. J. Infect. Dis. 190:63-71
143. + T cells in patients with X-linked lymphoproliferative syndrome. Mech. Ageing Dev. 126:855-65
144. Sharifi R, Sinclair JC, Gilmour KC, Arkwright PD, Kinnon C, et al. 2004. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 103:3821-27
145. + T cells against EBV-infected cells. Blood 105:4383-89
146. Milone MC, Tsai DE, Hodinka RL, Silverman LB, Malbran A, et al. 2005. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 105:994-96
147. Kikuta H, Taguchi Y, Tomizawa K, Kojima K, Kawamura N, et al. 1988. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawaski-like disease. Nature 333:455-57
148. Su IJ, Chen JY. 1997. The role of Epstein-Barr virus in lymphoid malignancies. Crit. Rev. Oncol. Hematol. 26:25-41
149. Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. 1997. Upregulation of tumor necrosis factor-α gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J. Clin. Invest. 100:1969-79
150. Chuang HC, Lay JD, Hsieh WC, Wang HC, Chang Y, et al. 2005. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood 106:3090-96
151. Smets F, Latinne D, Bazin H, Reding R, Otte J, et al. 2002. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73:1603-10
152. + T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 98:146-55
153. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, et al. 2002. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360:436-42
154. Khanna R, Moss D, Gandhi M. 2005. Technology insight: applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat. Clin. Pract. Oncol. 2:138-49
155. Ma CS, Nichols KE, Tangye SG. 2007. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu. Rev. Immunol. 25:337-79